Phase I Safety and Preliminary Efficacy of PM1009, a Bispecific Antibody Targeting TIGIT and PVRIG, in Patients with Advanced Solid Tumors.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined